Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
In the last decade, many reports have emphasized the potential of stem/precursor cells as intervention strategy to repair damaged tissue, providing new hope in the scientific and medical community for the treatment of various diseases and conditions considered as incurable before, such as neurodegenerative disorders [1,2], celiac disease [3,4], type 1 diabetes mellitus complications [5,6], muscle damage [7,8] and various blood cancers. Overall, experimental and clinical evidence shows that embryonic stem cells and, in a lesser extent, adult stem cells can generate various tissue types with the potential to replace damaged areas in the body, with a reduced risk of rejection and manageable side effects. These findings have opened new avenues for cell-based cancer therapies, whose majority are at experimental stage. These strategies are providing very encouraging results, particularly in clonal hematopoietic disorders like Myelodysplastic Syndromes (MDS) where the bloodforming cells damaged in the bone marrow are successfully repaired by Hematopoietic Stem Cell (HSC) transplantation with minimal toxicity and improved quality of life [9]..read more